Cancer-specific utility: clinical validation of the EORTC QLU-C10D in patients with glioblastoma
Our results indicate that the QLU-C10D is a valid utility measure to assess HRQoL in patients with glioblastoma. This facilitates the investigation of HRQoL profiles and utilities in this patient population by administering a single questionnaire, the EORTC QLQ-C30. Efficiency analyses point to higher statistical power of the QLU-C10D compared to the EQ-5D-3L.
Authors
- Simone Seyringer (ORCID: https://orcid.org/0000-0003-0689-9160)
- Micha J. Pilz (ORCID: https://orcid.org/0000-0003-4092-8797)
- Andrew Bottomley (ORCID: https://orcid.org/0000-0002-3067-5207)
- Madeleine T King (ORCID: https://orcid.org/0000-0002-9734-1973)
- Eva‐Maria Gamper (ORCID: https://orcid.org/0000-0002-1700-4054)
- Richard Norman (ORCID: https://orcid.org/0000-0002-3112-3893)
Institutions
- Johannes Kepler University of Linz (AT)
- The University of Sydney (AU)
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
- Curtin University (AU)
- European Organisation for Research and Treatment of Cancer (BE)
- University Hospital Innsbruck (AT)
Publication Details
- Journal
- The European Journal of Health Economics
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1007/s10198-024-01729-4
- Citations
- 3
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 3.39
Funders
- European Organisation for Research and Treatment of Cancer